Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM).

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT00994682

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:36:37.372674+00:00

Published At

2017-04-05T00:00:00+00:00

Record Updated At

2017-04-05

Results Posted At

2017-04-05

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Nonalcoholic Steatohepatitis", "Nonalcoholic Fatty Liver Disease", "Type 2 Diabetes Mellitus"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2017-04-05"

protocolSection.identificationModule.nctId

"NCT00994682"

protocolSection.identificationModule.officialTitle

"Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM)."

protocolSection.statusModule.overallStatus

"COMPLETED"

protocolSection.designModule.phases

["PHASE4"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

"2017-04-05"

Study condition terms

• Nonalcoholic Steatohepatitis (protocolSection.conditionsModule.conditions)
• Nonalcoholic Fatty Liver Disease (protocolSection.conditionsModule.conditions)
• Type 2 Diabetes Mellitus (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.